- Telo Genomics (TSXV: TELO, OTCQB: TDSGF) announced ASCO 2025 has accepted its MRD validation data for multiple myeloma.
- The company is developing two prognostic tests for monitoring MRD, leveraging the TeloView® technology.
- FDA's acceptance of MRD as a clinical endpoint supports faster drug approvals.
Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF), a leading biotech company in diagnostic and prognostic test development, announced that its abstract submission has been accepted by the American Society of Clinical Oncology (ASCO) for the 2025 Annual Meeting. The abstract highlights a concordance analysis between blood and marrow samples using the TeloView® Minimal Residual Disease (MRD) methodology. This significant acceptance underlines the potential impact of TeloView® applications in managing multiple myeloma (MM) post-transplantation.
The acceptance comes on the heels of a pivotal decision by the FDA's Oncologic Drugs Advisory Committee, which in April 2024 unanimously voted to recognize MRD as a clinical endpoint. This decision paves the way for the accelerated approval of new multiple myeloma therapies, thereby potentially expediting the availability of novel treatments in the market.
In collaboration with McGill University/Jewish General Hospital, Telo Genomics has been conducting clinical trials aimed at developing two liquid biopsy-based prognostic tests. The first test focuses on identifying and quantifying MRD cells in the blood post-marrow transplantation, while the second profiles isolated circulating MRD cells using the proprietary TeloView® technology to assess disease aggressiveness. These innovations position Telo at the forefront of precision medicine in oncology.
The ASCO Annual Meeting, recognized as one of the most prestigious oncology research conferences, will take place from May 30 to June 3, 2025, in Chicago, Illinois. More than 45,000 oncology professionals from around the world attend ASCO to advance cancer care through research and education, reinforcing its reputation as a premier platform for showcasing significant advancements in oncology research and treatment.
